In 2002, Wachsberger et al. demonstrated, by Western immunoblotting performed on 31 melanoma biopsies, a wide variability in the expression of both GLUT1 and HK and proposed the explanation that a broad spectrum of transporter activities could differently influence the response of patients to the same therapeutic treatment [14]. Here, SLC2A1 is linked to melanoma.